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Objectives. This study evaluated whether left ventricular mass 
increases during cellular or vascular (humoral) cardiac ailograft 
rejection. 
Background. An increase in left ventricular mass during cellu- 
lar cardiac allograft rejection has been described by other inves- 
tigators, although controversy has existed over the validity of 
these findings. Left ventricular mass changes have not been 
evaluated in the setting of vascular (humoral) cardiac ailograft 
rejection. 
Methods. To determine the effect of aUograft rejection on left 
ventricular mass, we retrospectively reviewed endomyocardial 
biopsy results and corresponding echocardiograms in 4l cardiac 
transplant recipients undergoing treatment for allograft rejection. 
Left ventricular mass was assessed by two-dimensional echocar- 
diography using the method of Schiller. Maintenance immuno- 
suppression included cyclosporine in all patients. 
Results. Although significant changes in left ventricular wall 
thickness, mass and dimensions were not observed in patients 
experiencing moderate or severe cellular allograft rejection (In- 
ternational Society for Heart and Lung Transplantation grades 
III and IV, n = 27), marked changes were noted in patients with 
vascular (humoral) rejection (n = 14). Patients with vascular 
rejection demonstrated an echocardiographic mean (_+SEM) in- 
crease in left ventricular wall mass (from 109 -+ 17 to 151 + 17 g), 
and left ventricular wall thickness (from 1.3 -+ 0.1 to 1.6 -+ 0.1 cm) 
during the rejection episode. Additionally, vascular rejection was 
associated with a trend toward an increase in left ventricular 
systolic dimension (from 2.6 -+ 0.1 to 3.0 -+ 0.2 cm) and a decrease 
in left ventricular fractional shortening and increased incidence of 
hemodynamic ompromise with rejection (50% for vascular vs. 
11% for cellular rejection). 
Conclusions. Left ventricular mass increases during episodes of 
vascular (humoral) rejection, but there is no significant change in 
left ventricular mass during cellular cardiac allograft rejection. 
(J Am Coil Cardio11995;25:922- 6) 
Cardiac allograft rejection is defined by histologic features that 
include the presence of lymphocytic nfiltration of the myocar- 
dium with or without myocyte necrosis (1). This histologic 
pattern is termed cellular rejection. A second form of acute 
allograft rejection, usually mediated by humoral immune 
mechanisms, was first recognized in renal transplantation. I  
cardiac transplantation it is associated with capillary injury 
without interstitial infiltrates. This "vascular" form of rejection 
is characterized by evidence of endothelial cell activation and 
can affect the coronary vessels in cardiac allografts (2). Com- 
pared with cellular ejection, vascular ejection is less common 
and occurs earlier after transplantation (3). Vascular allograft 
rejection is commonly resistant to standard forms of immuno- 
suppressive therapy, which may result in irreversible allograft 
dysfunction, markedly reduced allograft survival and reduced 
~atient survival (3-5). Several transplant centers have reported 
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that vascular ejection is associated with mortality rates of 44% 
to 80% (3,5). In addition, vascular ejection may be associated 
with a higher incidence of allograft coronary artery disease (6). 
There are limited light microscopic findings in vascular 
rejection that include endothelial cell activation or injury and, 
rarely, perivascular deposition of leukocytes. Immunofluores- 
cent findings are the mainstay in the diagnosis of vascular 
rejection and include deposition of complement and immuno- 
globulin in a vascular distribution as well as evidence of 
capillary leakage of fibrin (7). Unfortunately, this diagnosis 
may go undetected because immunofluorescent staining is not 
routinely performed in most centers. The reason for this is 
multifactorial: More tissue must be extracted from the endo- 
myocardial biopsy sample, processing of the biopsy sample 
requires expertise in immunofluorescencc, and treatment of 
vascular ejection is at best imperfect at this time. 
Since the early 1980s, its has been reported that left 
ventricular mass as measured by echocardiography increases in 
the setting of cardiac allograft rejection (8-11). Unfortunately, 
this finding is not specific for rejection, and its sensitivity is 
unknown. The magnitude of change in left ventricular mass 
may be small because other investigators have not found a 
consistent increase (10). To date, echocardiographic studies of 
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cardiac allograft rejection have focused on cellular rejection 
defined by the presence of lymphocytic nfiltrates and myocyte 
necrosis. The more recently described vascular ejection has 
not been evaluated by echocardiography. Our empiric obser- 
vations suggested that left ventricular wall thickness may 
increase markedly during a vascular ejection episode. There- 
fore, we retrospectively analyzed echocardiograms of patients 
with either vascular or cellular rejection for changes in left 
ventricular mass. 
Methods  
The purpose of this study was to measure the changes in left 
ventricular mass during cardiac allograft rejection and com- 
pare the changes observed in cellular versus vascular rejection. 
Patients. This was a retrospective study of patients who 
underwent ortbotopic ardiac transplantation between March 
1985 and November 1991. To be eligible for study, subjects 
were required to have had at least one episode of either 
vascular ejection that required enhancement of their immu- 
nosuppressive r gimen or moderate to severe cellular ejection 
(International Society of Heart and Lung Transplantation 
grades III and IV). In addition, subjects were required to have 
had echocardiography erformed before and during the rejec- 
tion episodes. The biopsy sample and echocardiogram ob- 
tained during the rejection episodes were acquired before 
treatment for rejection was initiated. All patients had mainte- 
nance immunosuppressive th rapy that included cyclosporine. 
Patients received antihypertensive medications a necessary to 
control hypertension. Of 44 eligible subjects, 3were excluded 
because of technically poor echocardiograms, leaving 41 sub- 
jects in the study, 27 with cellular ejection and 14 with treated 
vascular ejection. The mean time between the baseline and 
rejection studies was 46 days. 
Eehocardiographic measurements. M-mode, two-dimen- 
sional, color and pulsed and continuous wave Doppler exami- 
nations were performed using a Hewlett-Packard 1000 ultra- 
sound imaging system with a 2.5- or 5.0-MHz transducer, or 
both, from standard windows (12). Echocardiograms obtained 
on the date of endomyocardial biopsy-documented r jection 
(cellular or vascular) were compared with echocardiograms 
obtained on a separate control date when no rejection was 
present so that each patient served as his or her own control. 
Left ventricular diastolic and systolic dimensions and frac- 
tional shortening were measured using standard M-mode 
techniques (13). Left ventricular wall thickness and mass were 
measured using an off-line computerized analysis (Hewlett- 
Packard 1000 ultrasound imaging system) by one observer 
(E.A.G.) in blinded manner using the technique of Schiller et 
al. (14). Briefly, left ventricular volume was measured using a 
truncated ellipsoid model. Left ventricular endocardial volume 
was subtracted from left ventricular epicardial volume, which 
yielded the actual volume of the left ventricular muscle. This 
volume was multiplied by the constant 1.06 to calculate left 
ventricular muscle mass. At least six cardiac cycles were 
analyzed for each left ventricular mass measurement (three 
parasternal short-axis and three apical long-axis views). Ten 
tapes were resubmitted to the observer in blinded manner to 
assess reproducibility of the echocardiographic measurements. 
Variability between individual measurements was 3% for left 
ventricular thickness and 4% for left ventricular mass. To 
assess the reproducibility of these measurements over time, we 
analyzed acontrol group of 10 subjects for whom echocardio- 
grams were obtained concurrently with two successive biopsy 
samples that were without cellular or vascular ejection. The 
average difference between successive measurements of left 
ventricular mass was 4% (first study 104 _+ 4 g, second study 
100 + 4 g). 
Diagnosis of rejeetion. Endomyocardial biopsy was per- 
formed by the internal jugular approach with a Stanford- 
modified Caves bioptome. Three to six endomyocardial biopsy 
fragments per biopsy procedure were obtained and placed on 
saline-soaked filter paper and taken immediately to the labo- 
ratory, where a small representative portion of one biopsy 
fragment was frozen in OTC freezing compound for immuno- 
fluorescence studies. The remaining pieces were immediately 
immersed in phosphate-buffered 10% formalin and rapidly 
processed for histologic evaluation by routine methods. 
Hematoxylin- and eosin-stained sections and Masson 
trichrome-stained s ctions were evaluated for each patient (7). 
Cellular rejection was defined by modified Billingham 
criteria (1). Vascular rejection was defined by finding the 
combination ofprominent endothelial cell swelling or vasculi- 
tis, or both, on light microscopy, accompanied by prominent 
interstitial edema nd the vascular deposition of immunoglob- 
ulin, complement and interstitial fibrin by immunofluorescence 
(7). An example of vascular ejection is shown in Figure 1. 
Statistical analysis. All data are presented as mean value 
_+ SE. For continuous variables, differences between groups 
were evaluated by repeated-measures analysis of variance. For 
noncontinuous variables, differences between groups were 
compared with the Fisher exact est. Differences were consid- 
ered significant at p < 0.05. 
Results 
Patient characteristics are presented in Table 1. Patients 
were similar with regard to age, gender, etiology of heart 
failure, time after transplantation to occurrence of the rejec- 
tion episode and presence of a positive donor-specific lympho- 
cyte cross-match. OKT3 sensitization and hemodynamic com- 
promise (defined by the need for intravenous inotropic agents 
for allograft dysfunction during the rejection episode) were 
significantly more common in patients with vascular ejection. 
M-mode findings are shown in Table 2. There were trends 
toward an increase in left ventricular systolic dimension and a 
decrease in fractional shortening in the vascular rejection 
group. However, when analyzed by repeated-measures analysis 
of variance, these changes were not significantly different 
between cellular and vascular ejection groups. 
The most notable findings were in the variables measured 
with two-dimensional echocardiography. Left ventricular wall 
924 GILL ET AL JACC Vol. 25, No. 4 
LEFT VENTRICULAR MASS DURING REJECTION March 15, 1995:922-6 
Table 1. Clinical Characteristics of 41 Study Patients 
Cellular Rejection Vascular Rejection 
(n = 27) (n = 14) 
Age (yr) 39 _+ 3 46 ± 4 
Gender (M/F) 22/5 10/4 
Etiology of heart failure 
CAD 9 7 
IDC 16 7 
Other 2 
Time after transplantation (too) 4 _+ 1 2 ± 1 
Baseline blood pressure (ram Hg) 
Systolic 124 _+ 4 119 ± 5 
Diastolic 82 + 3 78 + 3 
Rejection blood pressure (mm Hg) 
Systolic 126 ± 4 120 ± 6 
Diastolic 80 _+ 2 77 _+ 4 
Positive cross-match l 1 
OKT3 sensitization 0 3* 
Hemodynamic compromise 3 (11%) 7 (50%)* 
*p < 0.05 versus cellular ejection. Data presented are mean value ± SEM 
or number (%) of patients. CAD = postinfarction cardiomyopathy; F = female; 
Hemodynamic compromise = allograft dysfunction requiring intravenous ino- 
tropic therapy; IDC = idiopathic dilated cardiomyopathy; M = male. 
nearly 20%, and wall mass by nearly 40%, during vascular 
rejection. 
Figure 1. A, Photomicrograph s owing the histologic appearance of early 
vascular rejection. Microvessels have swollen endothelial cells (arrow- 
heads), and there is prominent interstitial edema. B, Photomicrograph 
showing immunofluorescent findings in a case of moderate vascular 
rejection. The tissue was incubated with antibody directed against com- 
plement components (C3c). Immunoglobulin G showed identical ocal- 
ization (not shown). Complement deposits (V) are seen as white staining 
and are present only within vessel walls. C, Photomicrograph showing 
immunofluorescent findings in a case of moderate vascular rejection 
incubated with antibody directed against fibrin, which stains white. There 
is obvious perivascular fibrin staining (P) surrounding fibrin staining of 
vessels (V). Original magnification x250, reduced by 51%. 
thickness tended to increase, and left ventricular mass signifi- 
cantly increased, in patients treated for vascular rejection 
(Table 2, Fig. 2); left ventricular wall thickness increased by 
Discuss ion  
Previous studies. An increase in left ventricular mass in the 
setting of cardiac allograff rejection is thought o be due to an 
increase in myocardial interstitial edema or vascular leakage of 
fibrin, or both (7). However, there may be other reasons for 
increased left ventricular mass in cardiac transplant recipients, 
including fluid retention from heart failure or prednisone, left 
ventricular hypertrophy from hypertension and increased fi- 
brous tissue replacing myocardium following chronic rejection 
(11). Previous tudies of left ventricular mass changes during 
allograft rejection are quite heterogeneous, with some using 
M-mode criteria for measurement of left ventricular mass and 
others using two-dimensional methods. In addition, many of 
the studies were done before the routine use of cyclosporine 
(9-11). Some investigators (10,11) have suggested that the 
Table 2. Echocardiographic Features of Cardiac Allograft Rejection 
Vascular Cellular 
(n = 14) (n - 27) 
Baseline Rejection Baseline Rejection 
LVIDD (cm) 4.4 _+ 0.1 4.5 + 0.1 4.2 ± 0.1 4.3 _+ 0.1 
LVIDS (cm) 2.6 +_ 0.1 3.0 ± 0.2 2.5 + 0.1 2.6 _+ 0.1 
LVFS (%) 40 -+ 2 34 _+ 3 41 _+ 2 39 -+ 2 
LV wall thickness (cm) 1.3 -- 0.1 1.6 + 0.1 1.4 _+ 0.1 1.5 -+ 0.1 
LV wall mass (g) 109 _+ 17 151 _+ 17" 95 +_ 7 104 - 7 
*p < 0.05 vascular versus cellular rejection. Data presented are mean 
value _+ SEM. FS = fractional shortening; IDD = diastolic diameter; IDS = 
systolic diameter; LV = left ventricular. 
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Figure 2. Left ventricular mass at baseline (solid bars) and during 
either vascular or cellular rejection (crosshatched bars). Left ventric- 
ular mass increased significantly in subjects with vascular rejection 
compared with those with cellular rejection. The p value for repeated- 
measures analysis of variance is shown in parentheses along the 
abscissa. 
magnitude of change in left ventricular mass during rejection 
episodes is less with the use of cyclosporine immunosuppres- 
sign. Dawkins et al. (10), for example, found no change in left 
ventricular mass using M-mode techniques in one study after 
the advent of cyclosporine. However, Mastropolo et al. (9) did 
find a statistically significant increase in left ventricular mass 
during cellular rejection in 17 patients by means of two- 
dimensional echocardiographic methods in patients with im- 
munosuppression cyclosporine therapy. 
To our knowledge, the effects of vascular ejection on left 
ventricular mass have not been previously studied. In our 
subjects left ventricular mass increased uring vascular ejec- 
tion but not during cellular rejection. The typical findings on 
biopsy of vascular ejection include endothelial cell edema or 
vaseulitis, or both, on light microscopy and the vascular 
deposition of immunoglobulin a d complement by immuno- 
fluorescence t chniques. These abnormalities may be respon- 
sible for the observed increase in wall thickness either directly 
or indirectly by altering capillary permeability and thus increas- 
ing interstitial fluid, leading to deposition of interstitial fibrin. 
Several investigators (15,16) noted an increase in interstitial 
and vascular fibrin on immunocytochemical testing. Labarrere 
et al. (15) showed that these findings are always associated with 
a loss of endothelial ntithrombin III in arterioles and venules 
and a loss of arteriolar smooth muscle tissue plasminogen 
activator. These findings can be detected early in the posttrans- 
plant period and are associated with clinically significant 
cardiac ompromise and were confirmed by Hammond et al. 
(16). 
Clinical implications. The echocardiographic manifesta- 
tions of vascular rejection may be of considerable clinical 
importance. An increase in left ventricular mass detected by 
echocardiography may suggest the presence of vascular ejec- 
tion. However, our data require further verification in a larger 
population and a prospective valuation. 
Paulsen et al. (17) first demonstrated that echocardio- 
graphically derived indexes of diastolic function were abnor- 
mal in patients with acute allograft rejection. Since that time, 
Valantine t al. (18,19), Haverish et al. (20) and Desruennes t
al. (21) have demonstrated that Doppler indexes of diastolic 
function were abnormal in patients with rejection. In all these 
studies, a 5% to 20% incidence of false positive results has 
been noted. Although these "false positive" results are normal 
by cellular criteria on the endomyocardial biopsy, such patients 
may have undiagnosed vascular rejection because most centers 
do not routinely perform surveillance for vascular ejection. 
We advocate valuation for vascular rejection in these patients 
by endomyocardial biopsy and measurement of left ventricular 
mass. 
Study limitations. The present study has the usual imita- 
tions of retrospective valuations. The possible effects of 
sampling errors from endomyocardial biopsy on our findings 
are unknown. The number of cardiac allograft recipients with 
vascular ejection that required treatment was limited. How- 
ever, we did evaluate all patients treated for vascular ejection 
at our institution who had adequate data for review. The 
vascular rejection group had a significantly higher incidence of 
allograft dysfunction, resulting in hemodynamic compromise. 
It is possible that our results reflect a decrease in allograft 
function, not differences between the types of rejection. How- 
ever, the changes in left ventricular mass of patients with 
vascular rejection without hemodynamic compromise also 
were greater than changes observed with cellular ejection with 
hemodynamic compromise (data not presented). In addition, 
more patients with vascular ejection than those with cellular 
rejection became sensitized to OKT3. This finding is expected 
because OKT3 sensitization is strongly associated with vascular 
rejection (4). 
Conclusions. Vascular ejection is associated with a signif- 
icant increase in left ventricular mass that is not observed with 
cellular rejection. The significance of these changes is uncer- 
tain, but they suggest a role for alterations invascular perme- 
ability in this disorder. 
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